Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report

Lei Lei Wu

News Reporter

In 2020, the biotech market was propelled upward by Covid-19, as money flowed quickly into the industry. In December of that year, Faze Medicines launched …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: Two years af­ter launch, Third Rock-backed neu­ro start­up Faze Med­i­cines is clos­ing its doors — re­port

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report